Related Experiment Video
Updated: Aug 9, 2026

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
Published on: July 10, 2017
von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation
Karim Kentouche1, Felix Zintl, Dorothea Angerhaus
1Department of Hematology, Children's Hospital, Friedrich Schiller University, Jena, Germany. Karim.Kentouche@med.uni-jena.de
Abstract:
Transplantation-associated microangiopathy (TAM) is a severe complication of stem cell transplantation. Although TAM shares many features with idiopathic thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, the prognosis of TAM is worse. Clinical similarities and the observation that uncleaved ultralarge von Willebrand factor (ULVWF) multimers are found in the circulation of patients suffering from TAM suggest a defect in VWF proteolysis that may be due to a deficiency in ADAMTS13 activity. In this study the course of 28 consecutive patients, who received an allogeneic stem cell transplant was correlated to ADAMTS13 activity. Before stem cell transplantation, mean ADAMTS13 activity was within normal range. Within the first 8 weeks, mean activity declined to less than half the baseline activity. Furthermore, most of the patients showed normalization of ADAMTS13 activity. Low levels of ADAMTS13 activity were not correlated with clinical signs of thrombotic microangiopathy. However, two patients with clinical TAM had the lowest activity of all patients when suffering a severe bout of microangiopathy. Plasma exchange was not able to normalize ADAMTS13 deficiency in these patients, suggesting inactivation or consumption of ADAMTS13 activity in TAM.
Insights
Transplantation-associated microangiopathy (TAM) involves reduced ADAMTS13 activity, an enzyme crucial for regulating von Willebrand factor. This study observed declining ADAMTS13 levels post-transplant, particularly during severe TAM episodes.
Area of Science:
- Hematology
- Transplantation Medicine
- Vascular Biology
Background:
- Transplantation-associated microangiopathy (TAM) is a serious stem cell transplant complication with a poor prognosis.
- TAM shares features with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
- Defective VWF proteolysis, potentially due to reduced ADAMTS13 activity, is implicated in TAM.
Observation:
- This study monitored ADAMTS13 activity in 28 patients undergoing allogeneic stem cell transplantation.
- ADAMTS13 activity, initially normal, decreased significantly within 8 weeks post-transplant.
- Most patients showed eventual normalization of ADAMTS13 activity.
Findings:
- Low ADAMTS13 activity did not consistently correlate with clinical TAM.
- Two patients with severe TAM exhibited the lowest ADAMTS13 activity levels.
- Plasma exchange failed to restore ADAMTS13 levels in these patients, suggesting enzyme inactivation or consumption.
Implications:
- ADAMTS13 deficiency or dysfunction may play a role in TAM pathogenesis.
- Further research is needed to elucidate the precise mechanisms of ADAMTS13 involvement in TAM.
- Understanding ADAMTS13 dynamics could lead to improved TAM diagnostics and therapeutics.
Related Concept Videos
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Intracellular Signaling Affects Focal Adhesions
Some...
Clot Retraction and Fibrinolysis

